Bladder Cancer

The bladder transplant procedure involved a collaboration between the University of California, Los Angeles and the University of Southern California.

Panelists discuss how non–muscle-invasive bladder cancer (NMIBC) is staged, graded, and treated according to risk stratification, with detailed explanations of low-, intermediate-, and high-risk categories and corresponding treatment pathways.

“The key finding is [that] this might be, in itself, a novel risk factor for bladder cancer," says Laura E. Davis, MD.

"The use of telemedicine is heavily dependent on supportive legislature," write Tracey L. Krupski, MD, and Jeunice Owens-Walton, MD.

The phase 3 RC48-C016 trial met its primary end points.

The study was published in JCO Oncology Practice.

The data are to be presented at an upcoming medical conference.

The CR rate was 71% in patients with BCG-unresponsive NMIBC with CIS with or without papillary disease.

Data showed that physical function and self-reported frailty assessments were poorly correlated.

The Oncologic Drugs Advisory Committee meeting is scheduled for May 21, 2025.

"It’s a very good time to be taking care of patients with bladder cancer," says Joshua J. Meeks, MD, PhD.

“In this well-selected patient population, it is possible to treat with systemic therapy alone," says John L. Gore, MD, MS.

“[These are] very good numbers for these patients who otherwise would undergo a radical cystectomy," says Félix Guerrero-Ramos, MD, PhD, FEBU.

The sBLA for NAI was submitted to the FDA in March 2025.

A recap of the FDA submissions and regulatory decisions in urology from April 2025.

“It's going to be an important time for US urologists to identify that this is becoming the standard of care," says Joshua J. Meeks, MD, PhD.

The study population was able to avoid 952 cystoscopies and 70 CT scans, according to the investigators.

In cohort A, the cystectomy-free rate at 36 months was 84%.

"I would argue that UGN-102 may very well represent a well-tolerated alternative to TURBT as primary treatment for patients with low-grade disease,” says Sandip M. Prasad, MD, MPhil.

Joseph Jacob, MD, outlines key findings on TAR-200 monotherapy from cohort 2 of the SunRISe-1 study.

The investigators reported that the median Kaplan-Meier estimate of DOR was 24.2 months.

"97% [of patients] remain progression free, and 84.5% avoided cystectomy, highlighting cretostimogene’s bladder-sparing potential,” said Mark D. Tyson II, MD, MPH.

“In the patients with CIS, the probability of a continued complete response at 36 months was 92% vs 67.7%," said Neal D. Shore, MD, FACS.

Treatment with TARA-002 was associated with a 100% high-grade CR at any time in BCG-unresponsive participants.